Burning Rock Biotech Ltd
BNR6.440USD
+0.770+13.58%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
58.15MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Burning Rock Biotech Ltd Unternehmen
Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.
Unternehmensinformationen
BörsenkürzelBNR
Name des UnternehmensBurning Rock Biotech Ltd
IPO-datumJun 12, 2020
CEOMr. Yusheng Han
Anzahl der mitarbeiter674
WertpapierartOrdinary Share
GeschäftsjahresendeJun 12
AddresseNo. 5 Xingdao Ring Road North
StadtGUANGZHOU
BörseXetra
LandChina
Postleitzahl510005
Telefon
Websitehttps://www.brbiotech.com/
BörsenkürzelBNR
IPO-datumJun 12, 2020
CEOMr. Yusheng Han
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Feng Deng
Mr. Feng Deng
Director
Director
--
--
Ms. Xiaozhi Hu
Ms. Xiaozhi Hu
Senior Director in Finance
Senior Director in Finance
--
--
Ms. Wendy Hayes, CPA
Ms. Wendy Hayes, CPA
Independent Director
Independent Director
--
--
Dr. Lisa (Licen) Xu
Dr. Lisa (Licen) Xu
Independent Director
Independent Director
--
--
Mr. Yusheng Han
Mr. Yusheng Han
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Dr. Zhihong (Joe) Zhang, Ph.D.
Dr. Zhihong (Joe) Zhang, Ph.D.
Chief Technology Officer, Director
Chief Technology Officer, Director
--
--
Mr. Gang Lu
Mr. Gang Lu
Director
Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Feng Deng
Mr. Feng Deng
Director
Director
--
--
Ms. Xiaozhi Hu
Ms. Xiaozhi Hu
Senior Director in Finance
Senior Director in Finance
--
--
Ms. Wendy Hayes, CPA
Ms. Wendy Hayes, CPA
Independent Director
Independent Director
--
--
Dr. Lisa (Licen) Xu
Dr. Lisa (Licen) Xu
Independent Director
Independent Director
--
--
Mr. Yusheng Han
Mr. Yusheng Han
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Dr. Zhihong (Joe) Zhang, Ph.D.
Dr. Zhihong (Joe) Zhang, Ph.D.
Chief Technology Officer, Director
Chief Technology Officer, Director
--
--
Umsatzaufteilung
FY2019
FY2018
Keine Daten
Nach RegionCNY
Name
Umsatz
Anteil
China (Mainland)
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, Jun 13
Aktualisiert: Fri, Jun 13
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Northern Light Venture Capital
11.67%
Kynam Capital Management LP
11.01%
Lyfe Capital
9.23%
China Merchants Bank Co Ltd
5.12%
Lilly Asia Ventures
4.85%
Other
58.11%
Aktionäre
Aktionäre
Anteil
Northern Light Venture Capital
11.67%
Kynam Capital Management LP
11.01%
Lyfe Capital
9.23%
China Merchants Bank Co Ltd
5.12%
Lilly Asia Ventures
4.85%
Other
58.11%
Aktionärstypen
Aktionäre
Anteil
Private Equity
20.90%
Hedge Fund
12.92%
Investment Advisor/Hedge Fund
7.58%
Bank and Trust
5.13%
Venture Capital
4.85%
Sovereign Wealth Fund
4.49%
Corporation
3.92%
Investment Advisor
3.56%
Research Firm
0.45%
Other
36.20%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
59
5.76M
63.80%
+1.00M
2025Q1
66
5.77M
63.83%
+940.56K
2024Q4
74
5.50M
64.55%
+928.80K
2024Q3
93
5.26M
61.71%
+353.76K
2024Q2
109
5.27M
61.79%
+40.23K
2024Q1
122
5.30M
62.18%
-174.69K
2023Q4
137
5.24M
61.49%
-310.76K
2023Q3
208
5.51M
64.24%
-866.01K
2023Q2
220
5.57M
64.96%
-832.63K
2023Q1
226
5.60M
65.29%
-882.42K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Northern Light Venture Capital
1.05M
11.67%
--
--
Mar 31, 2025
Kynam Capital Management LP
994.88K
11.01%
--
--
Mar 31, 2025
Lyfe Capital
833.84K
9.23%
--
--
Mar 31, 2025
China Merchants Bank Co Ltd
462.99K
5.12%
--
--
Mar 31, 2025
Lilly Asia Ventures
438.42K
4.85%
+438.42K
--
Dec 31, 2023
GIC Private Limited
405.64K
4.49%
+405.64K
--
Dec 31, 2023
MFS Investment Management
367.00K
4.06%
-2.73K
-0.74%
Mar 31, 2025
Quantum Boundary Holdings Ltd
353.92K
3.92%
+350.62K
+10637.83%
Mar 31, 2025
Fidelity International
280.90K
3.11%
--
--
Mar 31, 2025
CRCM L.P.
226.29K
2.5%
-99.68K
-30.58%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Avantis Responsible Emerging Markets Equity ETF
0%
DFA Dimensional Emerging Markets Core Equity 2 ETF
0%
SPDR S&P Emerging Markets Small Cap ETF
0%
Avantis Responsible Emerging Markets Equity ETF
Anteil0%
DFA Dimensional Emerging Markets Core Equity 2 ETF
Anteil0%
SPDR S&P Emerging Markets Small Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Apr 26, 2024
Merger
10<1
Apr 26, 2024
Merger
10<1
Apr 26, 2024
Merger
10<1
Apr 26, 2024
Merger
10<1
Datum
Art
Verhältnis
Apr 26, 2024
Merger
10<1
Apr 26, 2024
Merger
10<1
Apr 26, 2024
Merger
10<1
Apr 26, 2024
Merger
10<1
